ChristopherGAzzoliMDFASCO

Oncology • Providence, RI

Thoracic Cancer

Director of Thoracic Oncology, Lifespan Cancer Institute; Associate Professor of Medicine, Brown University

Join to view full profile

Dr. Azzoli is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Azzoli's full profile

Already have an account?

Office
Lifespan Cancer Institute
593 Eddy Street, George 362
Providence, RI 02903
Fax+1 401-444-4184
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
Johns Hopkins UniversityResidency, Internal Medicine, 1996 - 1999
Johns Hopkins University School of MedicineClass of 1996

Certifications & Licensure

MA State Medical License 2012 - 2025
RI State Medical License 2018 - 2024
NY State Medical License 1999 - 2013
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2012-2014
Boston Magazine Castle Connolly, 2013
Top Doctors: New York Metro Area Castle Connolly, 2012-2013
America's Top Doctors for Cancer Castle Connolly, 2011-2013
New York Magazine: Top Doctors Castle Connolly, 2012
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Ph I:Bevacizumab + Chemotherapy in Pts w/Malig Pleural Effusion Due to Adv NSCLC Start of enrollment: 2005 Nov 01
Completed
Phase 1
Methylated Genes in Blood as Biomarkers for Advanced Lung Cancer Start of enrollment: 2003 Jan 01
Completed
Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer Start of enrollment: 2002 Mar 01
Completed
Phase 2
Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer Start of enrollment: 2008 May 01
Completed
Not Applicable
Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib Start of enrollment: 2010 Aug 01
Terminated
Phase 2
Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN) Start of enrollment: 2011 Oct 01
Completed
Phase 2
Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Metastatic Lung Cancer and Metastatic Melanoma Receiving Post-progression Immune Checkpoint Inhibitor Therapy Start of enrollment: 2018 Jan 17
Completed
Not Applicable
BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab Start of enrollment: 2021 Oct 05
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer.
Tej Tummala, Ashley Sanchez Sevilla Uruchurtu, Arielle De La Cruz, Kelsey E Huntington, Andrew George, Nicholas R Liguori, Leiqing Zhang, Lanlan Zhou, Abbas E Abbas, C...> ;Current Oncology. 2023 Oct 31
Authors' Response to "Letter to the Editor" Submitted by S. Wang and W. Liu (re: "Retrospective Study to Examine Prognostic Value of C-Reactive Protein in Patients Wit...
Christopher Azzoli, Lynn Huynh, Denise Yi, Mei S Duh, Beilei Cai> ;Clinical Lung Cancer. 2023 Sep 1
1 citations
Retrospective Study to Examine Prognostic Value of C-Reactive Protein in Patients With Surgically Resectable Non-Small-Cell Lung Cancer.
Christopher Azzoli, Lynn Huynh, Denise Yi, Mei S Duh, Beilei Cai> ;Clinical Lung Cancer. 2023 Jun 1
5 citations
Predictors of Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Followed by Consolidative Durvalumab.
Brett H Diamond, Neel Belani, Rebecca Masel, Kathryn DeCarli, Thomas DiPetrillo, Jaroslaw T Hepel, Christopher G Azzoli, Humera Khurshid, Abbas Abbas, Paul P Koffer> ;Advances in Radiation Oncology. 2022 Nov 28
18 citations
Prediction of lung malignancy progression and survival with machine learning based on pre-treatment FDG-PET/CT.
Brian Huang, John Sollee, Yong-Heng Luo, Ashwin Reddy, Zhusi Zhong, Jing Wu, Joseph Mammarappallil, Terrance Healey, Gang Cheng, Christopher Azzoli, Dana Korogodsky, P...> ;Ebiomedicine. 2022 Aug 1
2 citations
Preclinical studies with ONC201/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC).
Nicholas R Liguori, Ashley Sanchez Sevilla Uruchurtu, Leiqing Zhang, Abbas E Abbas, Young S Lee, Lanlan Zhou, Christopher G Azzoli, Wafik S El-Deiry> ;American Journal of Cancer Research. 2022 Jan 1
4 citations
Absence of Biomarker-Driven Treatment Options in Small Cell Lung Cancer, and Selected Preclinical Candidates for Next Generation Combination Therapies.
Nicholas R. Liguori, Young Lee, William Borges, Lanlan Zhou, Christopher G. Azzoli, Wafik S. El-Deiry> ;Frontiers in Pharmacology. 2021 Aug 31
2 citations
The effect that pathologic and radiologic interpretation of invasive and non-invasive areas in lung adenocarcinoma has on T-stage and treatment.
Jesse L. Hart, Mariana Canepa, Saurabh Agarwal, Shaolei Lu, Christopher G. Azzoli, Maria Garcia-Moliner> ;Annals of Diagnostic Pathology. 2021 Jul 20
130 citations
Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer.
Jamie E. Chaft, Andreas Rimner, Walter Weder, Christopher G. Azzoli, Mark G. Kris, Tina Cascone> ;Nature Reviews. Clinical Oncology. 2021 Apr 28
18 citations
Thoracic nuclear protein in testis (NUT) carcinoma: expanded pathological spectrum with expression of thyroid transcription factor-1 and neuroendocrine markers.
Yin P Hung, Athena L. Chen, Martin S. Taylor, Tiffany Huynh, Marina Kem, Martin K. Selig, G. Petur Nielsen, Jochen K. Lennerz, Christopher G. Azzoli, Ibiayi Dagogo-Jac...> ;Histopathology. 2021 Mar 12
4 citations
Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non-Small-Cell Lung Cancer.
Joel W. Neal, Daniel B. Costa, Alona Muzikansky, Joseph B. Shrager, Michael Lanuti, James Huang, Kavitha J Ramachandran, Deepa Rangachari, Mark S. Huberman, Zofia Piot...> ;JCO Precision Oncology. 2021 Feb 1
Commentary: Preoperative gefitinib for stage II-III non-small cell lung cancer with EGFR mutation: A stich in time, or delay from stiches?
Christopher G. Azzoli, Thomas Ng> ;The Journal of Thoracic and Cardiovascular Surgery. 2021 Feb 1
8 citations
Survival outcomes associated with corticosteroid use before chemoimmunotherapy in patients with advanced lung cancer
Mark N. Sorial, Justin P Huynh, Christopher G. Azzoli, Justin C. Liauw, Robert D. Brunault, Christine M. Collins, Andrew R. Zullo> ;European Journal of Cancer. 2021 Mar 1
1 citations
Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers.
Surendra Pal Chaudhary, Eunice L. Kwak, Katie L. Hwang, Jochen K. Lennerz, Ryan B. Corcoran, Rebecca S. Heist, Andrea L. Russo, Aparna Raj Parikh, Darrell R. Borger, L...> ;The Oncologist. 2020 Nov 1
2 citations
Non-Small Cell Lung Cancer in the Era of Personalized Medicine: Molecular Tests that Matter.
Christopher Del Prete, Christopher G. Azzoli> ;Rhode Island Medical Journal. 2020 Apr 1
95 citations
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.
Ibiayi Dagogo-Jack, Satoshi Yoda, Jochen K. Lennerz, Adam Langenbucher, Jessica J. Lin, Marguerite Rooney, Kylie Prutisto-Chang, Audris Oh, Nathaniel A. Adams, Beow Y....> ;Clinical Cancer Research. 2020 Feb 21
Commentary: Chemotherapy for stage IB large cell neuroendocrine carcinomas of lung: Convention becomes conviction
Thomas Ng, Christopher G. Azzoli> ;The Journal of Thoracic and Cardiovascular Surgery. 2020 May 1
2 citations
KRAS Mutation for Staging Resected Non-Small Cell Lung Cancer.
Mariana Canepa, Nimesh R. Patel, Roger C. Griffith, Thomas T. Ng, Christopher G. Azzoli> ;Journal of Thoracic Oncology. 2019 Jul 1
14 citations
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial
James M. Cleary, Nora Horick, Nadine Jackson McCleary, Thomas A. Abrams, Matthew B. Yurgelun, Christopher G. Azzoli, Douglas A. Rubinson, Gabriel A. Brooks, Jennifer A...> ;Cancer. 2019 Jul 1
129 citations
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer
Nathan A. Pennell, Joel W. Neal, Jamie E. Chaft, Christopher G. Azzoli, Pasi A. Jänne, Ramaswamy Govindan, Tracey L. Evans, Daniel B. Costa, Heather A. Wakelee, Rebecc...> ;Journal of Clinical Oncology. 2019 Jan 10
59 citations
Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer.
Varuna Nangia, Faria M. Siddiqui, Sean Caenepeel, Daria Timonina, Samantha J. Bilton, Nicole Phan, Maria Gomez-Caraballo, Hannah L. Archibald, Chendi Li, Cameron Frase...> ;Cancer Discovery. 2018 Dec 1
51 citations
Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions.
Zofia Piotrowska, Daniel B. Costa, Geoffrey R. Oxnard, Mark S. Huberman, Justin F. Gainor, Inga T. Lennes, Alona Muzikansky, Alice T. Shaw, Christopher G. Azzoli, Rebe...> ;Annals of Oncology. 2018 Oct 1
104 citations
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA
Ibiayi Dagogo-Jack, A. Rose Brannon, Lorin A. Ferris, Catarina D. Campbell, Jessica J. Lin, Katherine Schultz, Jennifer Ackil, Sara Stevens, Leila Dardaei, Satoshi Yod...> ;JCO Precision Oncology. 2018 Jan 23
58 citations
Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer.
Anna F. Farago, Christopher G. Azzoli> ;Translational Lung Cancer Research. 2017 Oct 1
229 citations
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
Nasser Hanna, David Johnson, Sarah Temin, Sherman Baker Jr, Julie Brahmer, Peter M Ellis, Giuseppe Giaccone, Paul J Hesketh, Ishmael Jaiyesimi, Natasha B Leighl, Grego...> ;Journal of Clinical Oncology. 2017 Oct 20
Join now to see all

Journal Articles

Oxford University Press Has Registered This DOI Pre-Publication
R S Heist, Z Piotrowska, C G Azzoli, A T Shaw, I T Lennes, L V Sequist, J F Gainor, Oxford University Press

Press Mentions

Roche’s IMpower010 Trial Results Warrant Evidence on Survival Impact for Tecentriq Adoption in Non-Small Cell Lung CancerJune 2nd, 2021
Merck’s Proposed Less Frequent Keytruda Dosing May Allow for Minor Uptake BoostNovember 19th, 2019